Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas. [revisión]
Por: Baro Fernández, María [Pediatría]
| Pérez Alonso, Vanessa [Pediatría].
Colaborador(es): Servicio de Pediatría-Neonatología.
Tipo de material: 
ArtículoEditor: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2016Descripción: 32(10):1939-45.Recursos en línea: Solicitar documento Resumen: Introduction: Pediatric low-grade gliomas (PLGG) are the most common primary central nervous system tumor in children. Patients in whom gross total resection can be achieved have an excellent overall (OS) and event-free survival (EFS) and do not require adjuvant therapy. However, children with unresectable tumors often experience multiple progressions and require additional treatment.
Conventional chemotherapy: Radiotherapy results in long-term tumor control, but it is associated with significant toxicity, making chemotherapy the preferred therapeutic option. Several chemotherapy combinations have been found to be successful in PLGG, but 5-year EFS has been below 60 % with most of them.
Molecular-based treatment: Recent molecular advances have led to a better understanding of the molecular pathways involved in the biology of LGG, allowing the development of promising tumor-specific, molecularly targeted therapies.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Revisión
|
PC17711 (Navegar estantería) | Disponible |
Formato Vancouver:
Fernández MB, Alonso VP. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas. Childs Nerv Syst. 2016 Oct;32(10):1939-45.
PMID: 27659836
Contiene 63 referencias
Introduction: Pediatric low-grade gliomas (PLGG) are the most common primary central nervous system tumor in children. Patients in whom gross total resection can be achieved have an excellent overall (OS) and event-free survival (EFS) and do not require adjuvant therapy. However, children with unresectable tumors often experience multiple progressions and require additional treatment.
Conventional chemotherapy: Radiotherapy results in long-term tumor control, but it is associated with significant toxicity, making chemotherapy the preferred therapeutic option. Several chemotherapy combinations have been found to be successful in PLGG, but 5-year EFS has been below 60 % with most of them.
Molecular-based treatment: Recent molecular advances have led to a better understanding of the molecular pathways involved in the biology of LGG, allowing the development of promising tumor-specific, molecularly targeted therapies.
No hay comentarios para este ejemplar.